Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Supercharged Charitable Investment Fund To Nurture UK's Biotech Ecosystem

Executive Summary

The UK’s largest medical charities, the Wellcome Trust and Cancer Research UK, have backed the formation of a bulked-up £1bn long-term investment fund from the bringing together of Syncona, the CRT Pioneer Fund and BACIT, with the aim of building a self-sustaining UK biotech ecosystem.

You may also be interested in...

Achilles Therapeutics Targets The Root Of Cancer

Emerging Company Profile: With funding from Cancer Research UK and Syncona – and a wealth of science from its founders – newly launched London-based immuno-oncology company Achilles Therapeutics, believes it has identified cancer's weak spot.

Engineered T-Cell Company Raises $56m And Lands New CEO

The UK's next-generation engineered T-cell immunotherapy company Autolus Ltd. has raised £40m ($56m) in a Series B financing that includes the first investment by the new UK investment firm, Perceptive Bioscience Investments Ltd., and funding from Woodford Investment Management LLP. The round brings Autolus's total funding to a respectable £70m in less than two years.

NightstaRx Boasts Advantage Over Spark In Inherited Retinal Disease

Spun out from the University of Oxford, new born NightstarRx is finding its feet in the biopharma field and has closed a $35m series B funding, with which it will boost its inherited retinal disease pipeline.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts